Publication Name	World Journal of Experimental Medicine
Manuscript ID	66156
Country	United States

Received	2021-03-30 22:02
Peer-Review Started	2021-03-21 19:28
To Make the First Decision
Return for Revision	2021-05-14 00:17
Revised	2021-05-23 20:24
Second Decision	2021-09-02 02:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-09-02 03:44
Articles in Press	2021-09-02 03:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-09-13 04:14
Publish the Manuscript Online	2021-09-16 08:41

ISSN	2220-315x (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Obstetrics & Gynecology
Manuscript Type	Minireviews
Article Title	Antenatal corticosteroids in COVID-19 perspective
Manuscript Source	Invited Manuscript
All Author List	Alex C Vidaeff, Kjersti M Aagaard and Michael A Belfort
Funding Agency and Grant Number
Corresponding Author	Alex C Vidaeff, MD, Professor, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Texas Childrens Hospital, Baylor College Medicine, 6651 Main St, Suite F1020, Houston, TX 77030, United States. vidaeff@bcm.edu
Key Words	Antenatal corticosteroids; COVID-19; Dexamethasone; Pregnancy; SARS-CoV-2; Preterm delivery
Core Tip	Evidence from the randomized evaluation of coronavirus disease 2019 therapy trial supports the use of dexamethasone in the setting of maternal respiratory disease requiring either invasive mechanical ventilation or oxygen alone but not for patients receiving no respiratory support. Dexamethasone will have the added benefit of promoting fetal maturity at < 34 wk gestation in cases at risk for preterm delivery. Fetal indications for antenatal corticosteroids should be limited to obstetrical indications resulting in a high probability of preterm delivery and indiscriminate usage of fluorinated corticosteroids for fetal maturation, regardless of disease stage, is unadvisable.
Publish Date	2021-09-16 08:41
Citation	Vidaeff AC, Aagaard KM, Belfort MA. Antenatal corticosteroids in COVID-19 perspective. World J Exp Med 2021; 11(4): 37-43
URL	https://www.wjgnet.com/2220-315x/full/v11/i4/37.htm
DOI	https://dx.doi.org/10.5493/wjem.v11.i4.37

Full Article (PDF)	WJEM-11-37.pdf
Full Article (Word)	WJEM-11-37.docx
Manuscript File	66156_Auto_Edited-JPY.docx
Answering Reviewers	66156-Answering reviewers.pdf
Audio Core Tip	66156-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	66156-Conflict-of-interest statement.pdf
Copyright License Agreement	66156-Copyright license agreement.pdf
Peer-review Report	66156-Peer-review(s).pdf
Scientific Misconduct Check	66156-Scientific misconduct check.pdf
Scientific Editor Work List	66156-Scientific editor work list.pdf